Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy
Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate consisting of the monoclonal antibody trastuzumab linked to the maytansinoid DM1 with potential antineoplastic activity and is approved for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. An analysis of the US Fo...
Saved in:
Main Authors: | Samy Hakroush, Svenja Wulf, Julia Gallwas, Björn Tampe |
---|---|
Format: | article |
Language: | EN |
Published: |
Frontiers Media S.A.
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/69660472ecad4e3d87607bcd9af7c51b |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
by: Salkeni MA, et al.
Published: (2021) -
Biopsia renal en el segundo trimestre del embarazo: Dos casos clínicos
by: Vukusich,Antonio, et al.
Published: (2013) -
Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
by: Linehan AS, et al.
Published: (2021) -
Association of karyomegalic interstitial nephritis with focal segmental glomerulosclerosis
by: Momal Tara Chand, et al.
Published: (2021) -
Similarities and Differences between COVID-19-Associated Nephropathy and HIV-Associated Nephropathy
by: Anqun Chen, et al.
Published: (2021)